Cell line · CVCL_1544
Papers87
1 to 20 of 87
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Do G4 ligands induce mitochondrial dysfunction without ROS induction. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GM-CSF Armed Oncolytic Adenovirus Enhances T-Cell Infiltration and Suppresses Local and Distal Tumor Growth. | Viruses | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor cell-intrinsic circular RNA circFNDC3B attenuates CD8+ T cells infiltration in non-small cell lung cancer. | Commun Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR). | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeted degradation of specific TEAD paralogs by small molecule degraders. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. | EMBO Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1544/papers